Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Dragana Milojkovic, Nicole Blijlevens, Yok-Lam Kwong, Uzma Zaidi, Fausto Castagnetti, Paolo Gallipoli, Maria Cristina Miggiano, Peter E Westerweel, Melissa Chen, M. Carmen Garcia Hernandez, William J. Kell, Pankit Vachhani, Neha Agarwal, Alessandra Colasante, Sridhar Meka, Aoife Smyth, Germano Ferreira, Jeroen J.W.M. Janssen

Blood (2023) 142 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2023-181937

Published: 2023

Journal Articles

Incidence, Interpretation and Management of Liver Function Abnormalities in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKI)

Harry F Robertson, Victoria Orovboni, Jeeyune Bahk, Richard Szydlo, Fiona R Fernando, Afzal Khan, Sarmad Toma, Chloe Hayden, Simone Claudiani, Andrew J Innes, Dragana Milojkovic, Jane F Apperley

Blood (2023) 142 (Supplement 1): 6370.

https://doi.org/10.1182/blood-2023-188740

Published: 2023

Journal Articles

Real-World Experience of Asciminib: Factors Associated with Response

Blood (2022) 140 (Supplement 1): 6796–6797.

https://doi.org/10.1182/blood-2022-165501

Published: 2022

Journal Articles

Total Body Irradiation Is Associated with Higher Prevalence of Cerebral Microbleeds in Haematopoietic Stem Cell Transplant Survivors

Jure Hederih, Asad Charania, Adam Waldman, Jiri Pavlu, Richard Szydlo, Dragana Milojkovic, Eduardo Olavarria, Renuka Palanicawandar, Camelia Vladescu, Jose Ros Soto, Andrew J. Innes, Nichola Cooper

Blood (2022) 140 (Supplement 1): 12910–12912.

https://doi.org/10.1182/blood-2022-168057

Published: 2022

Journal Articles

Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study

Kathy Dominy, Matthew Salmon, Richard Szydlo, Chloe Hayden, Helen E White, Mary Alikian, Dragana Milojkovic, Mhairi Copland, Letizia Foroni, Nicholas C.P. Cross, Richard E Clark, Jane F. Apperley

Blood (2022) 140 (Supplement 1): 9631–9632.

https://doi.org/10.1182/blood-2022-170375

Published: 2022

Journal Articles

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Jerald P. Radich, Chung Hoow Kok, Ekaterina Yu. Chelysheva, Jorge E. Cortes, Qian Jiang, Michael Mauro, Dragana Milojkovic, Beatriz Moiraghi, Franck E. Nicolini, Matilda Ongondi, Katia B Pagnano, Daniela Žácková, Delphine Rea, Nicola Evans, Timothy Hughes

Blood (2022) 140 (Supplement 1): 9617–9619.

https://doi.org/10.1182/blood-2022-165855

Published: 2022

Journal Articles

Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

Michael W. Deininger, Tim H Brummendorf, Jeffrey H. Lipton, Dragana Milojkovic, Leif Stenke, Eric Leip, Simon Purcell, Andrea Viqueira, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 3913–3915.

https://doi.org/10.1182/blood-2022-163276

Published: 2022

Journal Articles

Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast-Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose-Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial

Mhairi Copland, Daniel Slade, Graham McIlroy, Gillian Horne, Jennifer Byrne, Kate Rothwell, Kristian Brock, Hugues De Lavallade, Charles Craddock, Richard Clark, Matthew Smith, Rachel Fletcher, Rebecca Bishop, Dragana Milojkovic, Christina Yap

Blood (2021) 138 (Supplement 1): 312.

https://doi.org/10.1182/blood-2021-147972

Published: 2021

Journal Articles

Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial

Blood (2021) 138 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2021-148480

Published: 2021

Journal Articles

COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study

Katia B Pagnano, Chung Hoow Kok, Michael J. Mauro, Jorge E. Cortes, Nicola Evans, Qian Jiang, Dragana Milojkovic, Beatriz Moiraghi, Franck E. Nicolini, Matilda Ongondi, Daniela Zackova, Delphine Rea, Timothy P. Hughes

Blood (2021) 138 (Supplement 1): 634.

https://doi.org/10.1182/blood-2021-150026

Published: 2021

Journal Articles

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Claire Harrison, DM, FRCP, FRCPath, Joanna Baxter, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Thomas McKerrell, MD PhD, Aimee Jackson, BSc, MSc, Rachel S Fletcher, PhD, Adam J. Mead, MD PhD, Steve Knapper, BMBCh, MRCP, FRCPath, DM, Joanne Ewing, MD PhD, Nauman M Butt, MD, Manish Jain, MBBS, MRCP, FRCpath, Sebastian Francis, MBChB, FRCPath, MD, Fiona J Clark, FRCP, FRCPath, Jason Coppell, MBBS, Mary Frances McMullin, MDFRCP, FRCPath, Frances Wadelin, MB ChB, PhD FRCPath, Srinivasan Narayanan, FRCP, FRCPath, Dragana Milojkovic, Mark W. Drummond, PhD FRCPath, Mallika Sekhar, MBBS, MD, Maike Paramor, James Roberts, BSc, Rachel Glover, BSc, Erica Harris, MSc, Luigi Grassi, PhD, Alba Rodriguez-Meira, PhD, Jason Carroll, PhD FMedSci, José-Ezequiel Martín, PhD, Giuditta Corbizi Fattori, PhD, Zijian Fang, BSc, Anna L Godfrey, BMBCh, PhD, Simón Méndez-Ferrer, PhD

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-134764

Published: 2020

Journal Articles

Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia

Simone Claudiani, Carolina Rosadas, Myra McClure, Maryam Khan, Richard S. Tedder, Andrew J. Innes, Dragana Milojkovic, Jane Apperley, FRCP, FRCPath, MB

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-142454

Published: 2020

Journal Articles

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Tim H Brümmendorf, MD, Jorge E. Cortes, MD, Dragana Milojkovic, Carlo Gambacorti-Passerini, MD, Richard E. Clark, MA, MD MRCP, FRCPath, Philipp D le Coutre, MD, Valentín Garcia-Gutiérrez, MD PhD, Charles Chuah, MD, Vamsi Kota, MD, Jeffrey H. Lipton, MD PhD, Philippe Rousselot, MDPhD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Rafael Hurtado Monroy, MD, Eric Leip, Simon Purcell, Anne Yver, PharmD, Andrea Viqueira, MD, Michael W. Deininger, MD PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-137393

Published: 2020

Journal Articles

Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]

Mark W. Drummond, PhD FRCPath, Charlotte Gaskell, BSc, MSc, Claire Harrison, DM, FRCP, FRCPath, Adam J. Mead, MD PhD, Christina Yap, PhD CStat, Aimee E Jackson, BSc, MSc, Jennifer Byrne, FRCP, FRCPath, PhD, Fiona J Clark, FRCP, FRCPath, Srinivasan Narayanan, FRCP, FRCPath, David Bowen, MD, Tim C.P Somervaille, PhD FRCP, FRCPath, Emma Gudgin, MBBS, MRCP, FRCPath, PhD, Dragana Milojkovic, Rachel S Fletcher, PhD, Charlotte K Brierley, MRCP, MD, Steve Knapper, BMBCh, MRCP, FRCPath, DM

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-138437

Published: 2020

Journal Articles

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Daniel Slade, MSc, BSc (Hons), Jenny Byrne, MD PhD, Kristian Brock, MSc, BSc, Hugues De Lavallade, Charles Craddock, FRCP, FRCPath, Richard Clark, MBBS, MRCP, MRCPath, MD, Matthew Smith, MBBS, Rebecca Bishop, BSc, Dragana Milojkovic, MBBS, MD, Christina Yap, MSci, PhD CStat

Blood (2019) 134 (Supplement_1): 497.

https://doi.org/10.1182/blood-2019-125591

Published: 2019

Journal Articles

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

Blood (2019) 134 (Supplement_1): 498.

https://doi.org/10.1182/blood-2019-124430

Published: 2019

Journal Articles

Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Study By the Chronic Malignancies Working Party of EBMT

Blood (2019) 134 (Supplement_1): 3335.

https://doi.org/10.1182/blood-2019-121820

Published: 2019

Journal Articles

A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity

Blood (2019) 134 (Supplement_1): 4141.

https://doi.org/10.1182/blood-2019-131113

Published: 2019

Journal Articles

NF-κB-Dependent Activation of the Proteasome Components, PSMD1 and PSMD3, As a Mechanism of Resistance to Imatinib

Idaly Maria Olivas, BS, Joshua Lara, BS, Rebecca Ellwood, MS, Carme Ripoll Fiol, MS, Andres J Rubio, MS, Alfonso Enrique Bencomo, PhD, Mayra Alejandra Gonzalez, BS, Georgios Nteliopoulos, PhD, Alistair Reid, BSc, PhD, Dragana Milojkovic, MBBS, MD, Jane Apperley, MB, ChB, MD, Jamshid Sorouri Khorashad, MD PhD FRCPath, Anna M. Eiring, PhD

Blood (2019) 134 (Supplement_1): 2923.

https://doi.org/10.1182/blood-2019-126963

Published: 2019

Journal Articles

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Simone Claudiani, MD, Silvia Metelli, PhD, Rafiee Kamvar, BSc, Richard Szydlo, PhD, Afzal Khan, Jenny Byrne, MD PhD, Paolo Gallipoli, PhD, Simon J Bulley, Gillian A. Horne, MBChB BSc, MRCP, MRes, PhD, Kate Rothwell, BA MB BChir, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard E. Clark, MA, MD MRCP, FRCPath, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Dragana Milojkovic, MBBS, MD, Jane F. Apperley, MD FRCP, FRCPath, MB

Blood (2019) 134 (Supplement_1): 26.

https://doi.org/10.1182/blood-2019-131500

Published: 2019

NARROW

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Incidence, Interpretation and Management of Liver Function Abnormalities in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKI)

Real-World Experience of Asciminib: Factors Associated with Response

Total Body Irradiation Is Associated with Higher Prevalence of Cerebral Microbleeds in Haematopoietic Stem Cell Transplant Survivors

Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast-Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose-Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial

Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial

COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Study By the Chronic Malignancies Working Party of EBMT

A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity

NF-κB-Dependent Activation of the Proteasome Components, PSMD1 and PSMD3, As a Mechanism of Resistance to Imatinib

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only